<Anchor>
It seems that a clinical trial of the COVID-19 vaccine in the form of a single dose will be done soon. If successful in human clinical trials, the world's first edible coronavirus vaccine will be available.
Reporter Kim Do-kyun reports.
<Reporter>
The vaccine that has requested clinical trial approval from Israeli health authorities is Oravax's oral COVID-19 vaccine.
The vaccine is in the form of a single dose, and the company explained that the formation of immunity to COVID-19 was confirmed through an animal test in March.
If it succeeds in clinical trials on humans, it will become the world's first edible COVID-19 vaccine.
Unlike existing vaccines that require low temperature distribution, they are easy to store and distribute, so the company expected that it would be useful, especially in emerging countries where medical infrastructure is lacking.
The company also expects that the vaccine will be much more effective against COVID-19 mutation than the existing vaccine, and that it will have fewer side effects.
With thousands of clinical quantities manufactured in Europe, clinical approval is expected to take weeks.
---
In the midst of this, the European Medicines Agency has recommended the approval of the US pharmaceutical company Moderna's corona vaccine for teenagers between the ages of 12 and 17.
Based on the results of the study on 3,700 people, the Korea Drug Administration concluded that the effectiveness of moderna vaccines in this age group was similar to that of adults.
Currently, 200 million people, more than half of the adult population in the European Union, have been vaccinated, and the EU's goal is to have up to 70% of the adult population vaccinated by this summer.